

Aktuelle Publikationen von Mitarbeitern oder unter Beteiligung von Mitarbeitern der Klinik und Poliklinik für Psychiatrie und Psychotherapie im Jahr 2004

Articles, Editorial Material, Letters, News Items, Notes und Reviews

Abo-Salem OM, Hayallah AM, **Bilkei-Gorzo A**, Filipek B, **Zimmer A**, Müller CE. Antinociceptive effects of novel A2B adenosine receptor antagonists.
J Pharmacol Exp Ther. 2004;308(1): 358-66 (Impact(2006)=3.956)

Abou Jamra R, Schumacher J, Golla A, Richter C, Otte ACJ, **Schulze TG**, **Ohlraun S**, **Maier W**, **Rietschel M**, Cichon S, Propping P, Nöthen MM. Family-based association studies of alpha-adrenergic receptor genes in chromosomal regions with linkage to bipolar affective disorder.
Am J Med Genet B Neuropsychiatr Genet. 2004;126B: 79-81 (Impact(2006)=4.463)

Bailey A, Weber D, **Zimmer A**, **Zimmer AM**, Hourani SM, Kitchen I. Quantitative autoradiography of adenosine receptors and NBTI-sensitive adenosine transporters in the brains of mice deficient in the preproenkephalin gene.
Brain Res. 2004;1025(1-2): 1-9 (Impact(2006)=2.341)

Barkow K, **Heun R**, Ustün TB, Berger M, Bermejo I, Gaebel W, Härter M, Schneider F, Stieglitz RD, **Maier W**. Identification of somatic and anxiety symptoms which contribute to the detection of depression in primary health care.
Eur Psychiatry. 2004;19(5): 250-7 (Impact(2006)=1.463)

Barkow K, **Heun R**, Wittchen HU, Bedirhan Ustün T, **Gänsicke M**, **Maier W**. Mixed anxiety-depression in a 1 year follow-up study: shift to other diagnoses or remission?
J Affect Disord. 2004;79(1-3): 235-9 (Impact(2006)=3.138)

Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss HJ, Laux G, Müller-Oerlinghausen B, **Rao ML**, Riederer P, Zernig G. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.
Pharmacopsychiatry. 2004;37(6): 243-65 (Impact(2006)=2.849)

Baumann P, Hiemke C, Ulrich S, Gaertner I, **Rao ML**, Eckermann G, Gerlach M, Kuss HJ, Laux G, Müller-Oerlinghausen B, Riederer P, Zernig G. Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline.
Ther Drug Monit. 2004;26(2): 167-70 (Impact(2006)=3.032)

Bilkei-Gorzo A, **Racz I**, **Michel K**, **Zimmer A**, Klingmüller D, **Zimmer A**. Behavioral phenotype of preproenkephalin-deficient mice on diverse congenic backgrounds.
Psychopharmacology (Berl). 2004;176(3-4): 343-52 (Impact(2006)=3.625)

Bliesener N, **Yokusoglu H**, **Quednow BB**, Klingmüller D, **Kühn KU**. Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report.
Pharmacopsychiatry. 2004;37(4): 189-91 (Impact(2006)=2.849)

Chabane N, Millet B, Delorme R, **Lichtermann D**, Mathieu F, Laplanche JL, Roy I, Mouren MC, Hankard R, **Maier W**, Launay JM, Leboyer M. Lack of evidence for association between serotonin transporter gene (5-HTTLPR) and obsessive-compulsive disorder by case control and family association study in humans.
Neurosci Lett. 2004;363(2): 154-6 (Impact(2006)=2.092)

Cichon S, Buervenich S, Kirov G, Akula N, Dimitrova A, Green E, Schumacher J, Klopp N, Becker T, **Ohlraun S**, **Schulze TG**, **Tullius M**, **Gross MM**, Jones L, Krastev S, Nikolov I, Hamshere M, Jones I, Czerski PM, Leszczynska-Rodziewicz A, Kapelski P, Bogaert AV, Illig T, Hauser J, **Maier W**, Berrettini W, Byerley W, Coryell W, Gershon ES, Kelsoe JR, McInnis MG, Murphy DL, Nurnberger JI, Reich T, Scheftner W, O'Donovan MC, Propping P, Owen MJ, **Rietschel M**, Nöthen MM, McMahon FJ,

Craddock N. Lack of support for a genetic association of the XBP1 promoter polymorphism with bipolar disorder in probands of European origin.

Nat Genet. 2004;36(8): 783-4; author reply 784-5 (Impact(2006)=24.176)

Delorme R, Krebs MO, Chabane N, Roy I, Millet B, Mouren-Simeoni MC, **Maier W**, Bourgeron T, Leboyer M. Frequency and transmission of glutamate receptors GRIK2 and GRIK3 polymorphisms in patients with obsessive compulsive disorder.

Neuroreport. 2004;15(4): 699-702 (Impact(2006)=2.137)

Domschke K, Freitag CM, Kuhlenbäumer G, Schirmacher A, Sand P, Nyhuis P, Jacob C, Fritze J, **Franke P, Rietschel M**, Garritsen HS, Fimmers R, Nöthen MM, Lesch KP, Stögbauer F, Deckert J. Association of the functional V158M catechol-O-methyl-transferase polymorphism with panic disorder in women.

Int J Neuropsychopharmacol. 2004;7(2): 183-8 (Impact(2006)=5.184)

Ehrenreich H, Degner D, Meller J, Brines M, Béhé M, Hasselblatt M, Woldt H, **Falkai P**, Knerlich F, Jacob S, von Ahsen N, **Maier W**, Brück W, Rüter E, Cerami A, Becker W, Sirén AL. Erythropoietin: a candidate compound for neuroprotection in schizophrenia.

Mol Psychiatry. 2004;9(1): 42-54 (Impact(2006)=11.804)

Eiden LE, Schäfer MK, Weihe E, **Schütz B**. The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine.

Pflugers Arch. 2004;447(5): 636-40 (Impact(2006)=4.807)

Falkai P, Tepest R, Honer WG, **Dani I, Ahle G, Pfeiffer U, Vogeley K, Schulze TG, Rietschel M**, Cordes J, Schönell H, Gaebel W, **Kühn KU, Maier W**, Träber F, Block W, Schild HH, Schneider-Axmann T. Shape changes in prefrontal, but not parieto-occipital regions: brains of schizophrenic patients come closer to a circle in coronal and sagittal view.

Psychiatry Res Neuroimaging. 2004;132(3): 261-71 (Impact(2006)=2.755)

Falkai P, Tepest R, Schulze TG, Müller DJ, Rietschel M, Maier W, Träber F, Block W, Schild HH, Steinmetz H, Gaebel W, Honer WG, Schneider-Axmann T, **Wagner M**. Etiopathogenetic mechanisms in long-term course of schizophrenia.

Pharmacopsychiatry. 2004;37 Suppl 2: S136-40 (Impact(2006)=2.849)

Farmer A, Breen G, Brewster S, Craddock N, Gill M, Korszun A, **Maier W**, Middleton L, Mors O, Owen M, Perry J, Preisig M, Rietschel M, Reich T, Jones L, Jones I, McGuffin P. The Depression Network (DeNT) Study: methodology and sociodemographic characteristics of the first 470 affected sibling pairs from a large multi-site linkage genetic study.

BMC Psychiatry. 2004;4(1): 42 (Impact(2006)=0)

Feuchtl A, Bagli M, Stephan R, Frahnert C, Kölsch H, Kühn KU, Rao ML. Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile.

Pharmacopsychiatry. 2004;37(4): 180-8 (Impact(2006)=2.849)

Frank B, Niesler B, Nöthen MM, Neidt H, Propping P, Bondy B, Rietschel M, **Maier W**, Albus M, Rappold G. Investigation of the human serotonin receptor gene HTR3B in bipolar affective and schizophrenic patients.

Am J Med Genet B Neuropsychiatr Genet. 2004;131B(1): 1-5 (Impact(2006)=4.463)

Fric M, Laux G, Inn WA, **Rao ML**, Schmidmeier R, Eberl J, Kirchmeier T, Betzl F, Brunbauer A. Plasmaspiegel von Risperidon bei Alterspatienten mit Demenz.

Psychopharmakotherapie. 2004;11(3): 90-4 (Impact(2006)=0.19)

Grasmäder K, Verwohlt PL, Kühn KU, Dragicevic A, **von Widdern O, Zobel A**, Hiemke C, **Rietschel M, Maier W**, Jaehde U, **Rao ML**. Population pharmacokinetic analysis of mirtazapine.

Eur J Clin Pharmacol. 2004;60(7): 473-80 (Impact(2006)=2.029)

Grasmäder K, Verwohlt PL, Rietschel M, Dragicevic A, Müller M, Hiemke C, **Frey mann N, Zobel A, Maier W, Rao ML.** Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. *Eur J Clin Pharmacol.* 2004;60(5): 329-36 (Impact(2006)=2.029)

Gross G, Huber G. The discrepancy between scientific advances in psychiatry and the reality of treatment of psychoses. *Neurol Psychiat Brain Res.* 2004;11(4): 165-70 (Impact(2006)=0)

Gross G, Huber G. Die idiopathischen Psychosyndrome in der Sicht Werner Janzariks. *Fortschr Neurol Psychiatr.* 2004;72 Suppl 1: S7-13 (Impact(2006)=0.546)

Häfner H, Maurer K, Ruhrmann S, Bechdorf A, Klosterkötter J, **Wagner M, Maier W,** Bottlender R, Möller HJ, Gaebel W, Wölwer W. Early detection and secondary prevention of psychosis: facts and visions. *Eur Arch Psychiatry Clin Neurosci.* 2004;254(2): 117-28 (Impact(2006)=3.042)

Harvey RJ, Depner UB, Wässle H, Ahmadi S, Heindl C, Reinold H, Smart TG, Harvey K, **Schütz B, Abo-Salem OM, Zimmer A,** Poisbeau P, Welzl H, Wolfer DP, Betz H, Zeilhofer HU, Müller U. GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. *Science.* 2004;304(5672): 884-7 (Impact(2006)=30.028)

Heun R, Frey mann N, Granath DO, Stracke CP, **Jessen F, Barkow K,** Reul J. Differences of cerebral activation between superior and inferior learners during motor sequence encoding and retrieval. *Psychiatry Res Neuroimaging.* 2004;132(1): 19-32 (Impact(2006)=2.755)

Heun R, Jessen F, Klose U, Erb M, **Granath DO,** Grodd W. Response-related fMRI of veridical and false recognition of words. *Eur Psychiatry.* 2004;19(1): 42-52 (Impact(2006)=1.463)

Heun R, Ptok U, Kölsch H, Maier W, Jessen F. Contribution of apolipoprotein E and cathepsin D genotypes to the familial aggregation of Alzheimer's disease. *Dement Geriatr Cogn Disord.* 2004;18(2): 151-8 (Impact(2006)=2.511)

Höfgen B, Rietschel M, Ackenheil M, **Maier W.** Genetische Grundlagen der Schizophrenie. *Psychoneuro.* 2004;30: 603-5

Hösing VG, Schirmacher A, Kühlenbäumer G, Freitag C, Sand P, Schlesiger C, Jacob C, Fritze J, **Franke P, Rietschel M,** Garritsen H, Nöthen MM, Fimmers R, Stögbauer F, Deckert J. Cholecystokinin- and cholecystokinin-B-receptor gene polymorphisms in panic disorder. *J Neural Transm Suppl.* 2004;(68): 147-56 (Impact(2006)=1.792)

Holtzheimer PE, Avery D, **Schläpfer TE.** Antidepressant effects of repetitive transcranial magnetic stimulation. *Br J Psychiatry.* 2004;184: 541-2 (Impact(2006)=5.436)

Köhn D, Niedersteberg A, Wieneke A, Bechdorf A, Pukrop R, Ruhrmann S, Schultze-Lutter F, **Maier W,** Klosterkötter J. Frühverlauf schizophrener Ersterkrankungen mit langer Dauer der unbehandelten Erkrankung - eine vergleichende Studie. *Fortschr Neurol Psychiatr.* 2004;72(2): 88-92 (Impact(2006)=0.546)

Köhn D, Pukrop R, Niedersteberg A, Schultze-Lutter F, Ruhrmann S, Bechdorf A, **Berning J, Maier W,** Klosterkötter J. Wege in die Behandlung: Hilfesuchverhalten schizophrener Ersterkrankter. *Fortschr Neurol Psychiatr.* 2004;72(11): 635-42 (Impact(2006)=0.546)

Kölsch H, Heun R, Kerksiek A, Bergmann KV, **Maier W,** Lütjohann D. Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. *Neurosci Lett.* 2004;368(3): 303-8 (Impact(2006)=2.092)

Kölsch H, Linnebank M, Lütjohann D, **Jessen F**, Wüllner U, Harbrecht U, Thelen KM, Kreis M, Hentschel F, **Schulz A**, von Bergmann K, **Maier W**, **Heun R**. Polymorphisms in glutathione S-transferase omega-1 and AD, vascular dementia, and stroke. *Neurology*. 2004;63(12): 2255-60 (Impact(2006)=5.69)

Kölsch H, **Ptok U**, **Majores M**, **Schmitz S**, **Rao ML**, **Maier W**, **Heun R**. Putative association of polymorphism in the mannose 6-phosphate receptor gene with major depression and Alzheimer's disease. *Psychiatr Genet*. 2004;14(2): 97-100 (Impact(2006)=2.141)

Korszun A, Moskvina V, Brewster S, Craddock N, Ferrero F, Gill M, Jones IR, Jones LA, **Maier W**, Mors O, Owen MJ, Preisig M, Reich T, Rietschel M, Farmer A, McGuffin P. Familiality of symptom dimensions in depression. *Arch Gen Psychiatry*. 2004;61(5): 468-74 (Impact(2006)=13.936)

Kühn KU, Joe AY, **Meyer K**, Reichmann K, **Maier W**, **Rao ML**, Reinhardt MJ, Biersack HJ, **Quednow BB**. Neuroimaging and 5-HT_{2C} receptor polymorphism: a HMPAO-SPECT study in healthy male probands using mCPP-challenge of the 5-HT_{2C} receptor. *Pharmacopsychiatry*. 2004;37(6): 286-91 (Impact(2006)=2.849)

Kühn KU, **Quednow BB**, Landen H, Riedel M, **Thiel M**. Lebensqualität und Therapieerfolg in der ambulanten Schizophrenie-Therapie mit Flupentixol: Eine Anwendungsbeobachtung. *Fortschr Neurol Psychiatr*. 2004;72(7): 397-403 (Impact(2006)=0.546)

Linnebank M, Linnebank A, Jeub M, Klockgether T, Wüllner U, **Kölsch H**, **Heun R**, Koch HG, Suormala T, Fowler B. Lack of genetic dispositions to hyperhomocysteinemia in Alzheimer disease. *Am J Med Genet A*. 2004;131(1): 101-2 (Impact(2006)=2.063)

Linnebank M, Schmidt S, **Kölsch H**, Linnebank A, **Heun R**, Schmidt-Wolf IG, Glasmacher A, Fliessbach K, Klockgether T, Schlegel U, Pels H. The methionine synthase polymorphism D919G alters susceptibility to primary central nervous system lymphoma. *Br J Cancer*. 2004;90(10): 1969-71 (Impact(2006)=4.459)

Maier W. Ursachen der Schizophrenie. Das Wechselspiel von Genen und Umwelt. *Der Neurologe & Psychiater*. 2004;[5](1): 14-6

Maier W. Genetik der Depression. Gegenwärtiger Erkenntnisstand und Perspektiven. *Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz*. 2004;47: 487-92

Möller JC, Depboylu C, **Kölsch H**, Lohmüller F, Bandmann O, Gocke P, Du Y, Paus S, Wüllner U, Gasser T, Oertel WH, Klockgether T, Dodel RC. Lack of association between the interleukin-1 alpha (-889) polymorphism and early-onset Parkinson's disease. *Neurosci Lett*. 2004;359(3): 195-7 (Impact(2006)=2.092)

Mosimann UP, Schmitt W, Greenberg BD, **Kosel M**, Müri RM, Berkhoff M, Hess CW, Fisch HU, **Schläpfer TE**. Repetitive transcranial magnetic stimulation: a putative add-on treatment for major depression in elderly patients. *Psychiatry Res*. 2004;126(2): 123-33 (Impact(2006)=2.31)

Mowry BJ, Holmans PA, Pulver AE, Gejman PV, Riley B, Williams NM, Laurent C, **Schwab SG**, **Wildenauer DB**, Bauché S, Owen MJ, Wormley B, Sanders AR, Nestadt G, Liang KY, Duan J, Ribble R, Norton N, Soubigou S, **Maier W**, Ewen-White KR, DeMarchi N, Carpenter B, Walsh D, Williams H, Jay M, Albus M, Nertney DA, Papadimitriou G, O'Neill A, O'Donovan MC, Deleuze JF, Lerer FB, Dikeos D, Kendler KS, Mallet J, Silverman JM, Crowe RR, Levinson DF. Multicenter linkage study of schizophrenia loci on chromosome 22q. *Mol Psychiatry*. 2004;9(8): 784-95 (Impact(2006)=11.804)

Nöthen MM, **Rietschel M**, Propping P, **Maier W**. Fortschritte in der Ursachenforschung affektiver und schizophrener Störungen.

Dtsch Arztl. 2004;101: A3343-3347

Paus S, **Rietschel M**, **Schulze TG**, **Ohlraun S**, Diaconu CC, Van Den Bogaert A, **Maier W**, Propping P, Cichon S, Nöthen MM. Systematic screening for mutations in the human N-methyl-D-aspartate receptor 1 gene in schizophrenic patients from the German population.

Psychiatr Genet. 2004;14(4): 233-4 (Impact(2006)=2.141)

Pritchard CA, Hayes L, Wojnowski L, **Zimmer A**, Marais RM, Norman JC. B-Raf acts via the ROCKII/LIMK/cofilin pathway to maintain actin stress fibers in fibroblasts.

Mol Cell Biol. 2004;24(13): 5937-52 (Impact(2006)=6.773)

Quednow BB, **Kühn KU**, **Hönig K**, **Maier W**, **Wagner M**. Prepulse inhibition and habituation of acoustic startle response in male MDMA ('ecstasy') users, cannabis users, and healthy controls.

Neuropsychopharmacology. 2004;29(5): 982-90 (Impact(2006)=5.889)

Quednow BB, **Kühn KU**, **Stelzenmüller R**, **Hönig K**, **Maier W**, **Wagner M**. Effects of serotonergic and noradrenergic antidepressants on auditory startle response in patients with major depression.

Psychopharmacology (Berl). 2004;175(4): 399-406 (Impact(2006)=3.625)

Rothe C, Gutknecht L, Freitag C, Tauber R, Mössner R, **Franke P**, Fritze J, Wagner G, Peikert G, Wenda B, Sand P, Jacob C, **Rietschel M**, Nöthen MM, Garritsen H, Fimmers R, Deckert J, Lesch KP. Association of a functional 1019C>G 5-HT1A receptor gene polymorphism with panic disorder with agoraphobia.

Int J Neuropsychopharmacol. 2004;7(2): 189-92 (Impact(2006)=5.184)

Rothermundt M, **Falkai P**, Ponath G, Abel S, Bürkle H, Diedrich M, Hetzel G, Peters M, Siegmund A, Pedersen A, **Maier W**, Schramm J, Suslow T, Ohrmann P, Arolt V. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF.

Mol Psychiatry. 2004;9(10): 897-9 (Impact(2006)=11.804)

Schläpfer TE. Learning from the history of neuroscience: dogma and patient interests: comment to Dr. Fink's commentary.

J ECT. 2004;20(3): 137-8; discussion 138 (Impact(2006)=0.866)

Schläpfer T, **Kosel M**. Novel physical treatments for major depression: vagus nerve stimulation, transcranial magnetic stimulation and magnetic seizure therapy.

Curr Opin Psychiatry. 2004;17(1): 15-20 (Impact(2006)=1.081)

Schmaljohann J, Minnerop M, Karwath P, Gündisch D, **Falkai P**, Guhlke S, Wüllner U. Imaging of central nAChReceptors with 2-[18F]F-A85380: optimized synthesis and in vitro evaluation in Alzheimer's disease.

Appl Radiat Isot. 2004;61(6): 1235-40 (Impact(2006)=0.924)

Schütz B, **Mauer D**, Salmon AM, Changeux JP, **Zimmer A**. Analysis of the cellular expression pattern of beta-CGRP in alpha-CGRP-deficient mice.

J Comp Neurol. 2004;476(1): 32-43 (Impact(2006)=3.831)

Schumacher J, Jamra RA, Freudenberg J, Becker T, **Ohlraun S**, Otte AC, **Tullius M**, **Kovalenko S**, Bogaert AV, **Maier W**, **Rietschel M**, Propping P, Nöthen MM, Cichon S. Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder.

Mol Psychiatry. 2004;9(2): 203-7 (Impact(2006)=11.804)

Spell C, **Kölsch H**, Lütjohann D, Kerksiek A, Hentschel F, Damian M, von Bergmann K, **Rao ML**, **Maier W**, **Heun R**. SREBP-1a polymorphism influences the risk of Alzheimer's disease in carriers of the ApoE4 allele.

Dement Geriatr Cogn Disord. 2004;18(3-4): 245-9 (Impact(2006)=2.511)

Vogeley K, May M, Ritzl A, **Falkai P**, Zilles K, Fink GR. Neural correlates of first-person perspective as one constituent of human self-consciousness.
J Cogn Neurosci. 2004;16(5): 817-27 (Impact(2006)=5.197)

von Widdern S, Hässler F, **von Widdern O**, Richter J. Ein Jahrzehnt nach der Wiedervereinigung - Wie beurteilen sich Jugendliche einer nordostdeutschen Schülerstichprobe hinsichtlich ihrer psychischen Befindlichkeit?
Prax Kinderpsychol Kinderpsychiatr. 2004;53(9): 652-73 (Impact(2006)=0.308)

Xu K, **Lichtermann D**, Lipsky RH, **Franke P**, Liu X, Hu Y, Cao L, **Schwab SG**, **Wildenauer DB**, Bau CH, Ferro E, Astor W, Finch T, Terry J, Taubman J, **Maier W**, Goldman D. Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations.
Arch Gen Psychiatry. 2004;61(6): 597-606 (Impact(2006)=13.936)

Zobel A, **Barkow K**, **Schulze-Rauschenbach S**, **Von Widdern O**, **Metten M**, **Pfeiffer U**, **Schnell S**, **Wagner M**, **Maier W**. High neuroticism and depressive temperament are associated with dysfunctional regulation of the hypothalamic-pituitary-adrenocortical system in healthy volunteers.
Acta Psychiatr Scand. 2004;109(5): 392-9 (Impact(2006)=3.857)

Zobel A, **Maier W**. Endophänotypen--ein neues Konzept zur biologischen Charakterisierung psychischer Störungen.
Nervenarzt. 2004;75(3): 205-14 (Impact(2006)=0.711)

Zobel AW, **Schulze-Rauschenbach S**, **von Widdern OC**, **Metten M**, **Freymann N**, **Grasmäder K**, **Pfeiffer U**, **Schnell S**, **Wagner M**, **Maier W**. Improvement of working but not declarative memory is correlated with HPA normalization during antidepressant treatment.
J Psychiatr Res. 2004;38(4): 377-83 (Impact(2006)=3.7)

Zobel A, Wellmer J, **Schulze-Rauschenbach S**, **Pfeiffer U**, **Schnell S**, Elger C, **Maier W**. Impairment of inhibitory control of the hypothalamic pituitary adrenocortical system in epilepsy.
Eur Arch Psychiatry Clin Neurosci. 2004;254(5): 303-11 (Impact(2006)=3.042)

Bücher und Buchbeiträge

Falkai P, **Vogeley K**, Kamer T, **Tepest R**, Schneider-Axmann T, **Maier W** (2004) Brain morphological abnormalities in first-degree relatives of schizophrenic patients. In: Gattaz WF, Häfner H (Eds.) Search for the causes of schizophrenia, Vol. V. Steinkopff, Darmstadt (254-266).

Franke P, **Schildberg F** (2004) Gruppentherapie zur Abstinenz- und Motivationsstärkung bei opiatabhängigen Patienten (GAMOA): Ein verhaltenstherapeutisches Manual. DGVT-Verlag, Tübingen.

Kölsch H, **Heun R** (2004) Genetik gerontopsychiatrischer Erkrankungen am Beispiel der Alzheimer-Demenz. In: Bergener M, Hampel H, Möller H-J, Zaudig M (Hrsg.) Gerontopsychiatrie: Grundlagen, Klinik und Praxis. Wissenschaftliche Verlagsgesellschaft, Stuttgart.

Maier W (2004) Schizophrenie - eine kognitive Störung? In: Rüter E (Hrsg.) 7. Bad Homburger ZNS-Gespräche. Springer, Berlin (12-13).

Maier W, **Hawellek B** (2004) Neuentwicklungen in der Erforschung der Genetik der Schizophrenie. In: Möller H-J, Müller N (Hrsg.) Schizophrenie. Langzeitverlauf und Langzeittherapie. Springer, Wien (63-72).

Maier W, **Linz M** (2004) Geschichte der psychiatrischen Versorgung in Bonn und des Faches Psychiatrie und Psychotherapie an der Bonner Universität. In: Hippus H (Hrsg.) Universitätskolloquien zur Schizophrenie, Bd 2. Steinkopff, Darmstadt (73-82).

Maier W, Wagner M, Falkai P, Schwab SG (2004) Genetics of schizophrenia and the impact of neuropsychology. In: Gattaz WF, Häfner H (Eds.) Search for the causes of schizophrenia, Vol. V. Steinkopff, Darmstadt (267-277).

Rösler M, Trabert W, **Falkai P**, Haug H-J, **Maier W**, Caspari D, Stieglitz R-D (2004) Das AMDP-Modul zur Negativsymptomatik. In: Freyberger HJ, Möller H-J (Hrsg.) Die AMDP-Module. Hogrefe, Göttingen (126-150).

Schläpfer TE (2004) Transkranielle Magnetstimulation. In: Kasper S, Möller HJ (Eds.) Herbst/Winterdepression und Lichttherapie. Springer, Wien, New York (191-202).

Schläpfer TE, Kosel M (2004) Transcranial magnetic stimulation in depression. In: Lisanby HS (Hrsg.) New technologies in psychiatric treatment. American Psychiatric Press, Arlington.

Wagner M (2004) Genetische Aspekte der Neuropsychologie psychischer Störungen. In: Lautenbacher S, Gauggel S (Hrsg.) Neuropsychologie psychischer Störungen. Springer, Heidelberg (147-166).